Stifel Reiterates Buy Rating on Olema Pharmaceuticals (OLMA): Roche Ph3 outcome "not optimal for OLMA stock near term"
Tweet Send to a Friend
Stifel analyst Laura Prendergast reiterated a Buy rating and $48.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
